Latest News and Press Releases

LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- LEIDEN, Netherlands & CAMBRIDGE, Mass., November 3, 2022 -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”),...

In line with corporate strategy update in April, ProQR to focus exclusively on the development of the Axiomer® RNA editing technology platform across multiple therapeutic areas; update on initial...

ProQR is accelerating the development of its Axiomer® RNA base-editing technology platform across multiple therapeutic areas and will provide an update on first targets in H2 2022Company plans to...

LEIDEN, Netherlands & CAMBRIDGE, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...

Annual General Meeting of Shareholders to be held on June 30, 2022René Beukema joins management team as Chief Corporate Development Officer and General Counsel and is nominated to Management...

LEIDEN, Netherlands & CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...

Post-hoc analyses from Illuminate trial of sepofarsen demonstrate an encouraging efficacy signal when comparing active treatment and sham eyes to their corresponding contralateral eyes across multiple...

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...

Post-hoc analyses from Illuminate trial of sepofarsen demonstrate an encouraging efficacy signal when comparing active treatment and sham eyes to their corresponding contralateral eyes across multiple...